Advertisement


Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease

2024 ASCO Annual Meeting

Advertisement

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Crystal-XII is a randomized phase three study that compare adagrasib with docetaxel in previously treated non-small cell lung cancer, that harbored KRAS-G2LC mutation. Now this study is important. Now, as you probably know, KRAS-G2LC accounted for about 14% of all lung adenocarcinoma. And then the adagrasib, which is a covalent bonded inhibitor of the KRAS-G2LC, as demonstrated in the early phase two data, that there is actually promising response rate, progression-free survival and over-survival. And also NCCN had approved that this is a category 2A agent for patient with this mutation, and brain metastasis. However, we still need to prove it with the randomized study, and is the time that we can share with you the result. So a bit of the design. This is designed to enroll the patient with the KRAS-G2LC stage four. The patient can receive chemotherapy, and also immunotherapy either concurrently or sequentially. It's a randomized in a two-to-one fashion, total above 453 patient. Now with that, there is actually, the patient actually was able to dispose, and majority of the patient received the targeted drug, meaning at aggressive of 99% of patient, and the dosage absolute arm is about 92% patient. And overall, the progression pre-survival is much improved, with the actually median of 5.5 versus, 3.8 months, hazard ratio 0.58. And also there is a difference in the response rate. 32% versus 9%, and this is also translated into a duration of response of about 8.4 months versus about 5.3 months. There's another feature that's important, which is the intracranial response. So for a patient with the known brain metastasis, we have a intracranial response rate of 24% versus about 11%. Safety wise, actually the most common toxicity is diarrhea. And then with this, actually the patient is mostly grade one and two. And also there's some nausea and vomiting, which is actually well controlled. One toxicity that's not so clear is that there's a slight elevation of the blood creatinine. However, most of this, patient will be reversible upon c-section of the drug. So as a conclusion, I think the Crystal-12 study had confirmed the role of the adagrasib as a second line therapy for patient with the lung cancer, with the KRAS-G2LC, after failing the chemotherapy and immunotherapy. In the future, there is also the Crystal-7 study, which actually put adagrasib in the first line. It will be in combination with pembrolizumab, comparing to pembrolizumab alone in patient with actually a PTPS score of over 50%.

Related Videos

Multiple Myeloma

Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI

Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more accurately in patients with either newly diagnosed or relapsed multiple myeloma, thus translating into potentially better outcomes (Abstract 7512).

Skin Cancer

Pauline Funchain, MD, and Caroline Robert, MD, PhD, on Melanoma: New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab

Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).

Kidney Cancer

Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as geneexpression signatures for tumorinduced proliferation, PDL1 status, or the mutation status of RCC driver genes.

Lymphoma

Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients with diffuse large B-cell lymphoma. Response rates were reported to be high, and most patients proceeded to transplant (Abstract 7032).

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable stage III melanoma compared with adjuvant nivolumab (LBA2)

Advertisement

Advertisement




Advertisement